Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | MAG | P20916 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.35 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20235169 | 0.87 | MAPK1 (0.49) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL13968092 | 0.84 | MAPK1 (0.62) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL21947412 | 0.83 | LGALS3 (0.56) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL15081898 | 0.83 | LGALS3 (0.56) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL26471206 | 0.81 | MAPK1 (0.43) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL21695250 | 0.80 | MAPK1 (0.50) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL26473755 | 0.80 | ALDH1A1 (0.47) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL19546052 | 0.80 | MAPK1 (0.47) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL26471213 | 0.79 | BDNF (0.44) | MAPK1ALDH1A1THRBLGALS3LGALS8 | |
| SCHEMBL12214020 | 0.78 | LGALS3 (0.43) | MAPK1ALDH1A1THRBLGALS3LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133656-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | SHOICHET, MOLLY SANDRA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230133656-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | SHOICHET, MOLLY SANDRA (CA) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133656-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | CD44, UACA, ALDH1A2 | MAPK1 3667/4885ALDH1A1 160/4885THRB 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.